Dyne Therapeutics (DYN) Accumulated Depreciation (2019 - 2026)
Dyne Therapeutics (DYN) posted quarterly Accumulated Depreciation of $9.7 million for Q2 2026, up 26.7% year-over-year from $7.7 million in Q2 2025, and up 6.11% quarter-over-quarter from $9.2 million in Q1 2026.
Dyne Therapeutics (DYN) Accumulated Depreciation (2019 - 2026) Analysis & Trends
Dyne Therapeutics (DYN) has reported Accumulated Depreciation for 8 consecutive years, with $9.7 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Accumulated Depreciation rose 26.7% year-over-year to $9.7 million; the TTM figure through Jun 2026 stood at $9.7 million (up 26.7% YoY), while the FY2025 annual figure was $8.7 million, up 28.76% from the prior year.
- Accumulated Depreciation grew to $9.7 million in Q2 2026 per DYN's latest filing, from $9.2 million in the prior quarter.
- Across five years, Accumulated Depreciation topped out at $9.7 million in Q2 2026 and bottomed at $2.4 million in Q1 2022.
- Historically, Accumulated Depreciation has averaged $5.9 million across 5 years, with a median of $5.9 million in 2024.
- Annual changes were most pronounced in 2022 — Accumulated Depreciation soared 95.3% — and 2025, when it rose 25.98%.
- Dyne Therapeutics' Accumulated Depreciation stood at $3.6 million in 2022, then soared by 45.72% to $5.3 million in 2023, then grew by 28.08% to $6.8 million in 2024, then advanced by 28.76% to $8.7 million in 2025, then gained by 11.55% to $9.7 million in 2026.
- Business Quant data shows DYN's Accumulated Depreciation at $9.7 million in Q2 2026, $9.2 million in Q1 2026, and $8.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Dyne Therapeutics | 4.26 Bn | 4.26 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.73 Mn |
| Mar 31, 2026 | 9.17 Mn |
| Dec 31, 2025 | 8.72 Mn |
| Sep 30, 2025 | 8.20 Mn |
| Jun 30, 2025 | 7.68 Mn |
| Mar 31, 2025 | 7.18 Mn |
| Dec 31, 2024 | 6.77 Mn |
| Sep 30, 2024 | 6.51 Mn |
| Jun 30, 2024 | 6.07 Mn |
| Mar 31, 2024 | 5.67 Mn |
| Dec 31, 2023 | 5.29 Mn |
| Sep 30, 2023 | 4.89 Mn |
| Jun 30, 2023 | 4.46 Mn |
| Mar 31, 2023 | 4.03 Mn |
| Dec 31, 2022 | 3.63 Mn |
| Sep 30, 2022 | 3.27 Mn |
| Jun 30, 2022 | 2.87 Mn |
| Mar 31, 2022 | 2.41 Mn |
| Dec 31, 2021 | 1.98 Mn |
| Sep 30, 2021 | 1.74 Mn |